11
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Racial and Ethnic Disparities in Cancer Care During the COVID-19 Pandemic

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Key Points

          Question

          Did racial and ethnic minority adults with cancer in the United States experience more cancer care delays and adverse social and economic effects than White adults during the COVID-19 pandemic?

          Findings

          In this survey study of 1240 US adults with cancer, Black and Latinx adults reported experiencing higher rates of delayed cancer care and more adverse social and economic effects than White adults.

          Meaning

          This study suggests that the COVID-19 pandemic is associated with disparities in the receipt of timely cancer care among Black and Latinx adults.

          Abstract

          Importance

          The full effect of the COVID-19 pandemic on cancer care disparities, particularly by race and ethnicity, remains unknown.

          Objectives

          To assess whether the race and ethnicity of patients with cancer was associated with disparities in cancer treatment delays, adverse social and economic effects, and concerns during the COVID-19 pandemic and to evaluate trusted sources of COVID-19 information by race and ethnicity.

          Design, Setting, and Participants

          This national survey study of US adults with cancer compared treatment delays, adverse social and economic effects, concerns, and trusted sources of COVID-19 information by race and ethnicity from September 1, 2020, to January 12, 2021.

          Exposures

          The COVID-19 pandemic.

          Main Outcomes and Measures

          The primary outcome was delay in cancer treatment by race and ethnicity. Secondary outcomes were duration of delay, adverse social and economic effects, concerns, and trusted sources of COVID-19 information.

          Results

          Of 1639 invited respondents, 1240 participated (75.7% response rate) from 50 US states, the District of Columbia, and 5 US territories (744 female respondents [60.0%]; median age, 60 years [range, 24-92 years]; 266 African American or Black [hereafter referred to as Black] respondents [21.5%]; 186 Asian respondents [15.0%]; 232 Hispanic or Latinx [hereafter referred to as Latinx] respondents [18.7%]; 29 American Indian or Alaska Native, Native Hawaiian, or multiple races [hereafter referred to as other] respondents [2.3%]; and 527 White respondents [42.5%]). Compared with White respondents, Black respondents (odds ratio [OR], 6.13 [95% CI, 3.50-10.74]) and Latinx respondents (OR, 2.77 [95% CI, 1.49-5.14]) had greater odds of involuntary treatment delays, and Black respondents had greater odds of treatment delays greater than 4 weeks (OR, 3.13 [95% CI, 1.11-8.81]). Compared with White respondents, Black respondents (OR, 4.32 [95% CI, 2.65-7.04]) and Latinx respondents (OR, 6.13 [95% CI, 3.57-10.53]) had greater odds of food insecurity and concerns regarding food security (Black respondents: OR, 2.02 [95% CI, 1.34-3.04]; Latinx respondents: OR, 2.94 [95% CI, [1.86-4.66]), financial stability (Black respondents: OR, 3.56 [95% CI, 1.79-7.08]; Latinx respondents: OR, 4.29 [95% CI, 1.98-9.29]), and affordability of cancer treatment (Black respondents: OR, 4.27 [95% CI, 2.20-8.28]; Latinx respondents: OR, 2.81 [95% CI, 1.48-5.36]). Trusted sources of COVID-19 information varied significantly by race and ethnicity.

          Conclusions and Relevance

          In this survey of US adults with cancer, the COVID-19 pandemic was associated with treatment delay disparities and adverse social and economic effects among Black and Latinx adults. Partnering with trusted sources may be an opportunity to overcome such disparities.

          Abstract

          This survey study assesses whether the race and ethnicity of patients with cancer was associated with disparities in cancer treatment delays and adverse social and economic effects during the COVID-19 pandemic.

          Related collections

          Most cited references49

          • Record: found
          • Abstract: found
          • Article: not found

          Structural racism and health inequities in the USA: evidence and interventions

          The Lancet, 389(10077), 1453-1463
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found
            Is Open Access

            Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls

            Most studies have some missing data. Jonathan Sterne and colleagues describe the appropriate use and reporting of the multiple imputation approach to dealing with them
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study

              Summary Background Since a national lockdown was introduced across the UK in March, 2020, in response to the COVID-19 pandemic, cancer screening has been suspended, routine diagnostic work deferred, and only urgent symptomatic cases prioritised for diagnostic intervention. In this study, we estimated the impact of delays in diagnosis on cancer survival outcomes in four major tumour types. Methods In this national population-based modelling study, we used linked English National Health Service (NHS) cancer registration and hospital administrative datasets for patients aged 15–84 years, diagnosed with breast, colorectal, and oesophageal cancer between Jan 1, 2010, and Dec 31, 2010, with follow-up data until Dec 31, 2014, and diagnosed with lung cancer between Jan 1, 2012, and Dec 31, 2012, with follow-up data until Dec 31, 2015. We use a routes-to-diagnosis framework to estimate the impact of diagnostic delays over a 12-month period from the commencement of physical distancing measures, on March 16, 2020, up to 1, 3, and 5 years after diagnosis. To model the subsequent impact of diagnostic delays on survival, we reallocated patients who were on screening and routine referral pathways to urgent and emergency pathways that are associated with more advanced stage of disease at diagnosis. We considered three reallocation scenarios representing the best to worst case scenarios and reflect actual changes in the diagnostic pathway being seen in the NHS, as of March 16, 2020, and estimated the impact on net survival at 1, 3, and 5 years after diagnosis to calculate the additional deaths that can be attributed to cancer, and the total years of life lost (YLLs) compared with pre-pandemic data. Findings We collected data for 32 583 patients with breast cancer, 24 975 with colorectal cancer, 6744 with oesophageal cancer, and 29 305 with lung cancer. Across the three different scenarios, compared with pre-pandemic figures, we estimate a 7·9–9·6% increase in the number of deaths due to breast cancer up to year 5 after diagnosis, corresponding to between 281 (95% CI 266–295) and 344 (329–358) additional deaths. For colorectal cancer, we estimate 1445 (1392–1591) to 1563 (1534–1592) additional deaths, a 15·3–16·6% increase; for lung cancer, 1235 (1220–1254) to 1372 (1343–1401) additional deaths, a 4·8–5·3% increase; and for oesophageal cancer, 330 (324–335) to 342 (336–348) additional deaths, 5·8–6·0% increase up to 5 years after diagnosis. For these four tumour types, these data correspond with 3291–3621 additional deaths across the scenarios within 5 years. The total additional YLLs across these cancers is estimated to be 59 204–63 229 years. Interpretation Substantial increases in the number of avoidable cancer deaths in England are to be expected as a result of diagnostic delays due to the COVID-19 pandemic in the UK. Urgent policy interventions are necessary, particularly the need to manage the backlog within routine diagnostic services to mitigate the expected impact of the COVID-19 pandemic on patients with cancer. Funding UK Research and Innovation Economic and Social Research Council.
                Bookmark

                Author and article information

                Journal
                JAMA Netw Open
                JAMA Netw Open
                JAMA Network Open
                American Medical Association
                2574-3805
                14 July 2022
                July 2022
                14 July 2022
                : 5
                : 7
                : e2222009
                Affiliations
                [1 ]Division of Oncology, Department of Medicine, Stanford University, Stanford, California
                [2 ]Medical Services, Veterans Affairs Palo Alto Health Care System, Palo Alto, California
                [3 ]Department of Epidemiology and Population Health, Stanford University, Stanford, California
                [4 ]Department of Psychology, Ponce Health Sciences University, Ponce Research Institute, Ponce, Puerto Rico
                [5 ]Battle Creek Veterans Affairs Medical Center–Clinical Neuropsychology Clinic, Battle Creek, Michigan
                [6 ]The Latino Cancer Institute, San Jose, California
                [7 ]Department of Medicine, University of Chicago, Chicago, Illinois
                [8 ]St Peter’s Health Partners Cancer Care, Albany, New York
                [9 ]Dana Farber Cancer Institute, Boston, Massachusetts
                Author notes
                Article Information
                Accepted for Publication: May 14, 2022.
                Published: July 14, 2022. doi:10.1001/jamanetworkopen.2022.22009
                Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2022 Patel MI et al. JAMA Network Open.
                Corresponding Author: Manali I. Patel, MD, MPH, MS, Division of Oncology, Department of Medicine, Stanford University, 875 Blake Wilbur Dr, Stanford CA 94305 ( manalip@ 123456stanford.edu ).
                Author Contributions: Dr Patel had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
                Concept and design: Patel.
                Acquisition, analysis, or interpretation of data: All authors.
                Drafting of the manuscript: Patel, Ferguson, Duron, Hlubocky, Infantado, Julian, Maingi.
                Critical revision of the manuscript for important intellectual content: Patel, Ferguson, Castro, Pereira-Estremera, Armaiz-Peña, Hlubocky, Nuqui, Nortey, Steck, Bondy, Maingi.
                Statistical analysis: Patel, Ferguson, Hlubocky, Bondy.
                Obtained funding: Patel.
                Administrative, technical, or material support: Patel, Castro, Pereira-Estremera, Armaiz-Peña, Hlubocky, Infantado, Nuqui, Julian, Nortey, Steck, Maingi.
                Supervision: Patel.
                Conflict of Interest Disclosures: Dr Pereira-Estremera reported receiving salary from Tiber Health Public Benefit Corp during the conduct of the study. No other disclosures were reported.
                Funding/Support: Dr Patel’s research in this publication was supported, in part, by the National Institute on Minority Health and Health Disparities of the National Institutes of Health under award K23MD013474. Drs Castro and Armaiz-Peña were supported by the National Institutes of Health under award R21MD013674. Dr Patel and Ms Duron received research funding from the California Initiative to Advance Precision Medicine, which supported, in part, the research reported in this publication.
                Role of the Funder/Sponsor: The National Institute on Minority Health and Health Disparities of the National Institutes of Health and the California Initiative to Advance Precision Medicine did not play a role in the design and conduct of the study; collection, management, analysis, or interpretation of the data; preparation, review, or approval of the manuscript; or the decision to submit the manuscript for publication.
                Disclaimer: The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
                Article
                zoi220621
                10.1001/jamanetworkopen.2022.22009
                9284331
                35834248
                40cf330a-11b3-45ba-a5b0-f39a3cffc881
                Copyright 2022 Patel MI et al. JAMA Network Open.

                This is an open access article distributed under the terms of the CC-BY License.

                History
                : 1 November 2021
                : 14 May 2022
                Categories
                Research
                Original Investigation
                Online Only
                Oncology

                Comments

                Comment on this article